法国BioAlliance Pharma 
成立于1997 年。 主要发展治疗癌症、病毒性疾病 ( 如 HIV) 以及伺机性感染等医药市场

Created in 1997, BioAlliance Pharma develops its activities and focuses them on rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections – to respond to the needs of specialist physicians, particularly in the hospital setting.

The Company designs and manufactures innovative products, based on active pharmaceutical ingredients already recognized on the market with a proven efficacy and tolerance profile, as well as developing new entities. It more specifically targets diseases for which the medical needs are insufficiently met and where the phenomenon of drug resistance leads to particularly serious consequences.

Our teams have the key competencies required to identify, design, develop and register drugs in Europe and the USA. Our development choices enable us to balance the risks in our product portfolio and to accelerate market launch of our products.

Positioning ourselves on our targeted markets, we have a European sales force and pursue an active license policy with industrial partners, particularly in the United States and Asia. This strategy allows us to diversify our direct and indirect revenues, while capitalizing on our structures and promoting synergies.